Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD I MARCUS

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1841451937
CMS profile
310960
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$40,447.08

256 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD I MARCUS

NPI 1841451937 · CMS profile ID 310960

Allopathic & Osteopathic Physicians / Ophthalmology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841451937?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841451937?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841451937?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841451937?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

256 matching records · $40,447.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 256 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 256.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mallinckrodt Hospital Products Inc. $37.9003/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103936 CMS
Mallinckrodt Hospital Products Inc. $2.0603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103940 CMS
Mallinckrodt Hospital Products Inc. $4.0803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103944 CMS
Alimera Sciences, Inc. $95.0003/20/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092831922 CMS
Alimera Sciences, Inc. $6,475.0003/20/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092832941 CMS
Alimera Sciences, Inc. $1,390.0003/20/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092835541 CMS
Astellas Pharma US Inc $350.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450410 CMS
Alimera Sciences, Inc. $24.3403/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092839065 CMS
Apellis Pharmaceuticals, Inc. $2.4703/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020349 CMS
Apellis Pharmaceuticals, Inc. $28.1603/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020351 CMS
Genentech USA, Inc. $23.2203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133005061 CMS
Bausch & Lomb Americas Inc. $21.2403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338476 CMS
Bausch & Lomb Americas Inc. $0.7003/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338478 CMS
Regeneron Healthcare Solutions, Inc. $21.9103/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114108073 CMS
Astellas Pharma US Inc $29.0503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139304252 CMS
Sandoz Inc. $27.1203/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089367248 CMS
ABBVIE INC. $27.3503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964810 CMS
ABBVIE INC. $3.1203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964812 CMS
Astellas Pharma US Inc $105.3703/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139304424 CMS
Astellas Pharma US Inc $7.6303/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139304448 CMS
Bausch & Lomb Americas Inc. $400.0003/06/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338486 CMS
Dutch Ophthalmic, USA $152.1203/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154792472 CMS
ABBVIE INC. $25.2503/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964808 CMS
Apellis Pharmaceuticals, Inc. $6.9002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020337 CMS
Astellas Pharma US Inc $350.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453486 CMS
Regeneron Healthcare Solutions, Inc. $7.8502/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114108071 CMS
Alimera Sciences, Inc. $1,390.0002/27/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092824953 CMS
Mallinckrodt Hospital Products Inc. $25.5502/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103932 CMS
Harrow Eye, LLC $20.6002/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145608966 CMS
Genentech USA, Inc. $24.4602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133005033 CMS
Alimera Sciences, Inc. $22.7902/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092839953 CMS
Alimera Sciences, Inc. $19.9902/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092840732 CMS
Alimera Sciences, Inc. $24.4902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092828640 CMS
ABBVIE INC. $19.7502/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964804 CMS
ABBVIE INC. $9.1802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964806 CMS
Bausch & Lomb Americas Inc. $22.8802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338474 CMS
Coherus Biosciences Inc. $30.4702/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278110 CMS
Mallinckrodt Hospital Products Inc. $18.8902/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103928 CMS
Mallinckrodt Hospital Products Inc. $5.7102/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103923 CMS
Coherus Biosciences Inc. $37.4101/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278100 CMS
Regeneron Healthcare Solutions, Inc. $303.5001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114108069 CMS
Alimera Sciences, Inc. $24.9001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092828179 CMS
Bausch & Lomb Americas Inc. $2,475.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338468 CMS
Mallinckrodt Hospital Products Inc. $24.3901/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145103919 CMS
Apellis Pharmaceuticals, Inc. $19.4201/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020371 CMS
Bausch & Lomb Americas Inc. $0.5501/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338470 CMS
Bausch & Lomb Americas Inc. $20.2701/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140338472 CMS
Regeneron Healthcare Solutions, Inc. $23.3101/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114108067 CMS
Alimera Sciences, Inc. $24.0901/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092839223 CMS
ABBVIE INC. $22.2401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104964802 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,406.33 87
PY2020 $14,333.12 96
PY2021 $16,148.36 158
PY2022 $18,634.29 172
PY2023 $16,549.63 209
PY2024 $40,447.08 256
PY2025 $34,756.22 215

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $31,438.00 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Global Development $573.00 11/24/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186086
Principal investigator 1 Astellas Pharma Global Development $831.00 11/24/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186090
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186082
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186084
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 10/10/2025 Non-covered Recipient Entity
SIGHT MEDICAL DOCTORS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184249769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 10/10/2025 Non-covered Recipient Entity
SIGHT MEDICAL DOCTORS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184249771
Principal investigator 1 Astellas Pharma Global Development $1,675.00 10/02/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186092
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/14/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186072
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186064
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186066
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186068
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186070
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186074
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186076
Principal investigator 1 Astellas Pharma Global Development $7,793.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186078
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186080